住院精神分裂症患者抗精神病药联合治疗的影响因素分析

摘要

Objective:To explore the influencing factors of antipsychotic polypharmacy in inpatients with schizophrenia. Method:A continuous sample of 801 schizophrenic inpatients was enrolled. Patients'socio-de-mographic data,clinical characteristics and prescriptions were recorded and compared between the inpatients with antipsychotic polypharmacy and with antipsychotic monopharmacy. Associations were analyzed by multiple Logistic regression. Results:Three hundred and four patients (45. 4%)received antipsychotic polypharma-cy,284 (78. 0%)of whom combined with clozapine or olanzapine. Multiple Logistic regression analysis indica-ted that age of onset,times of hospitalization,length of stay and whether to use clozapine or olanzapine were as-sociated with antipsychotic polypharmacy (P<0. 05),which accounted for 23. 2% variance of the antipsychotic polypharmacy. Conclusion:Compared with schizophrenic inpatients with antipsychotic monopharmacy,pa-tients with antipsychotic polypharmacy demonstrate younger age of onset,more times of hospitalization,longer length of stay and were more likely to use clozapine or olanzapine in combination.%目的:探讨住院精神分裂症患者抗精神病药联合治疗的影响因素.方法:回顾性分析连续入组住院的801例精神分裂症患者的社会人口学资料、临床疾病相关资料,比较接受单一抗精神病药治疗的患者和接受抗精神病药联合治疗的患者在出院日处方信息资料上的差异,并进行回归分析.结果:364例(45.4%)患者接受抗精神病药联合治疗,其中284例(78.0%)联用氯氮平或奥氮平.多因素Logistic回归分析显示,患者的起病年龄、住院次数、住院天数及有无联用氯氮平或奥氮平治疗进入方程(P<0.05),回归模型对患者接受单一抗精神病药治疗或抗精神病药联合治疗具有23.2%的解释度(Nagelkerke R2=0.232).结论:精神分裂症患者起病年龄小、住院次数多、住院时间长以及更有可能联用氯氮平或奥氮平是抗精神病药联合治疗的影响因素.